After market entry, manufacturers may need more than complaint trending and literature review. They may need structured post-market clinical data from registries, follow-up investigations, surveys, utilisation studies, or targeted evidence-generation programmes that answer specific questions about real-world use.
Qmed supports that execution across Europe. We can run a defined post-market study, reinforce an existing programme, or help clients structure a broader post-market evidence workstream with the right clinical and regulatory interfaces from the start.
What this service covers
Support can include PMCF investigations, observational studies, registries, user follow-up activities, survey-based programmes, site coordination, monitoring, data handling, safety oversight, vendor management, analysis coordination, reporting, and close-out.
That support can be delivered end to end or as a set of clearly defined work packages. Some clients need an operational partner to take ownership. Others need senior reinforcement where the study design already exists but delivery capacity does not.
Typical situations
Some have reached the point where a notified body, internal quality team, or CER update has made the evidence gap impossible to ignore. Others are scaling commercial use and need stronger post-market data to support continued confidence in safety and performance.
For startups, this can be the first time post-market work becomes a real operational programme. For more experienced manufacturers, the issue is often bandwidth, coordination across countries, or bringing a loose programme back under tighter control.
Talk to Qmed
Tell us what your post-market plan needs to deliver, where the study work will run, and which parts of execution you want Qmed to own.